Deutsche Bank Ag\ C4 Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 39,180 shares of CCCC stock, worth $158,679. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,180

Previous 29,848 31.27%

Holding current value

$158,679

Previous $137,000 62.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.43 - $7.38 $41,340 - $68,870	9,332 Added 31.27%	39,180 $223,000
Q2 2024 Aug 14, 2024	BUY	$4.05 - $8.1 $120,884 - $241,768	29,848 New	29,848 $137,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $25,302 - $73,621	8,162 Added 45.93%	25,932 $81,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $1,523 - $2,877	281 Added 1.61%	17,770 $104,000
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $7,540 - $11,991	-939 Reduced 5.1%	17,489 $153,000
Q2 2022 Aug 11, 2022	SELL	$5.06 - $26.46 $43,323 - $226,550	-8,562 Reduced 31.72%	18,428 $139,000
Q1 2022 May 13, 2022	SELL	$19.99 - $33.23 $580,709 - $965,331	-29,050 Reduced 51.84%	26,990 $654,000
Q4 2021 Feb 11, 2022	BUY	$29.39 - $46.86 $936,189 - $1.49 Million	31,854 Added 131.7%	56,040 $1.81 Million
Q3 2021 Nov 04, 2021	BUY	$35.91 - $50.5 $83,562 - $117,513	2,327 Added 10.65%	24,186 $1.08 Million
Q2 2021 Aug 11, 2021	BUY	$30.39 - $42.18 $445,061 - $617,726	14,645 Added 203.01%	21,859 $828,000
Q1 2021 May 13, 2021	SELL	$31.96 - $46.5 $20,710 - $30,132	-648 Reduced 8.24%	7,214 $266,000
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $179,253 - $291,287	7,862 New	7,862 $260,000

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $198M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account